4'-Hydroxyflurbiprofen

4'-Hydroxyflurbiprofen

SCHEMBL6450842

CC(C(=O)O)c1ccc(-c2ccc(O)cc2)c(F)c1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.97
CYP2C19 P33261 3/20 0.97
CYP2C9 P11712 2/20 0.97
CYP3A4 P08684 1/20 0.97
AKR1C3 P42330 9/20 0.78
AKR1C2 P52895 9/20 0.78
PTGS2 P35354 4/20 0.78
PTGS1 P23219 3/20 0.78
MEN1 O00255 2/20 0.78
KMT2A Q03164 2/20 0.78
PSEN1 P49768 2/20 0.78
PSEN2 P49810 2/20 0.78
APH1B Q8WW43 2/20 0.78
NCSTN Q92542 2/20 0.78
APH1A Q96BI3 2/20 0.78
PSENEN Q9NZ42 2/20 0.78
FABP2 P12104 1/20 0.78
TSHR P16473 1/20 0.78
AKR1C4 P17516 1/20 0.78
ADRA2B P18089 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4'-Hydroxyflurbiprofen SCHEMBL7040151 1.00 APP (0.97) APPCYP2C19CYP2C9CYP3A4AKR1C3
SCHEMBL2778899 0.98 APP (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3
SCHEMBL17524312 0.91 APP (0.81) APPCYP2C19CYP2C9CYP3A4AKR1C3
SCHEMBL1679257 0.91 APP (0.81) APPCYP2C19CYP2C9CYP3A4AKR1C3
SCHEMBL9667811 0.89 AKR1C3 (0.80) APPCYP2C19CYP2C9CYP3A4AKR1C3
Flurbiprofen SCHEMBL10029029 0.88 AKR1C3 (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3
Flurbiprofen SCHEMBL8755275 0.88 AKR1C3 (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3
Esflurbiprofen SCHEMBL505817 0.88 AKR1C3 (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3
Flurbiprofen SCHEMBL8754978 0.88 AKR1C3 (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3
Tarenflurbil SCHEMBL26131 0.88 AKR1C3 (1.00) APPCYP2C19CYP2C9CYP3A4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119541903-B Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-06-13 CN claimed
CN-119541903-A Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-02-28 CN claimed
CN-119541903-B Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-06-13 CN disclosed
CN-119541903-A Method for identifying effectiveness of gastrodia elata extract in preventing and treating parkinsonism 中国农业科学院农产品加工研究所 2025-02-28 CN disclosed
CN-116924910-A Impurity removing method for flurbiprofen axetil 南京优科生物医药股份有限公司 2023-10-24 CN disclosed
CN-114814026-A Impurity detection method of flurbiprofen axetil 南京优科生物医药股份有限公司 2022-07-29 CN disclosed
US-20160038448-A1 THE INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURBIPROFEN AND FLURBIPROFEN DERIVATIVES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2016-02-11 US disclosed
US-20160038448-A1 THE INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURBIPROFEN AND FLURBIPROFEN DERIVATIVES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2016-02-11 US disclosed
WO-2014159772-A2 INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURIPROFEN AND FLURIPROFEN DERIVATIVES THE RESEARCH FOUNDATION FOR THE STATW UNIVERSITY OF NEW YORK (US) 2014-10-02 WO disclosed
US-20050288375-A1 Method and composition for treating neurodegenerative disorders MYRIAD GENETICS, INCORPORATED (US) 2005-12-29 US disclosed
WO-2003003012-A1 IDENTIFICATION OF INTERACTING MOLECULES MEDIMOLECULAR PTY. LTD. (AU) 2003-01-09 WO disclosed
US-6100260-A ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-08 US disclosed
US-4008208-A Compositions having inhibited ability to promote platelet aggregation or fibrin clot formation THE UPJOHN COMPANY (US) 1977-02-15 US disclosed
US-3975371-A Aromatic azo sulfonylnitrene compounds THE UPJOHN COMPANY (US) 1976-08-17 US disclosed
US-3954583-A Photochemical process THE UPJOHN COMPANY (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038448-A1 THE INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURBIPROFEN AND FLURBIPROFEN DERIVATIVES IAPP, AMY2A, APP APP 3/4885CYP2C19 858/4885CYP2C9 645/4885
US-20050288375-A1 Method and composition for treating neurodegenerative disorders GRIN2A, GRIN2B, GRIN3A APP 8/4885CYP2C19 76/4885CYP2C9 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.